Enoximone
From Wikipedia, the free encyclopedia
![]() |
|
Clinical data | |
---|---|
Trade names | Perfan |
AHFS/Drugs.com | International Drug Names |
Routes of administration |
Intravenous |
ATC code | C01CE03 (WHO) |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 50% (oral) |
Protein binding | 85% |
Metabolism | Liver (oxidation) |
Biological half-life | 4 to 10 hours |
Excretion | Renal (60 to 70%) |
Identifiers | |
|
|
CAS Number | 77671-31-9 ![]() |
PubChem (CID) | 53708 |
DrugBank | DB04880 ![]() |
ChemSpider | 48492 ![]() |
UNII | C7Z4ITI7L7 ![]() |
KEGG | D04004 ![]() |
ChEMBL | CHEMBL249856 ![]() |
Chemical and physical data | |
Formula | C12H12N2O2S |
Molar mass | 248.302 g/mol |
3D model (Jmol) | Interactive image |
Melting point | 255 to 258 °C (491 to 496 °F) (decomposes) |
|
|
|
|
(verify) |
Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure and is selective for phosphodiesterase 3.[1]
Synthesis[edit]
Prepn: BE 883856 (1980 to Richardson-Merrell); R. A. Schnettler et al., U.S. Patent 4,405,635 (1983 to Merrell-Dow)
References[edit]
- ^ Boldt J, Suttner S (September 2007). "Combined use of ultra-short acting beta-blocker esmolol and intravenous phosphodiesterase 3 inhibitor enoximone". Expert Opin Pharmacother. 8 (13): 2135–47. doi:10.1517/14656566.8.13.2135. PMID 17714066.
- ^ Schnettler, Richard A.; Dage, Richard C.; Grisar, J. Martin (1982). "4-Aroyl-1,3-dihydro-2H-imidazol-2-ones, a new class of cardiotonic agents". Journal of Medicinal Chemistry. 25 (12): 1477–1481. doi:10.1021/jm00354a017. ISSN 0022-2623.
![]() |
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |